341 related articles for article (PubMed ID: 31526394)
1. Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma.
Zhang J; Liu S; Ye Q; Pan J
Mol Cancer; 2019 Sep; 18(1):140. PubMed ID: 31526394
[TBL] [Abstract][Full Text] [Related]
2. Neddylation Blockade Diminishes Hepatic Metastasis by Dampening Cancer Stem-Like Cells and Angiogenesis in Uveal Melanoma.
Jin Y; Zhang P; Wang Y; Jin B; Zhou J; Zhang J; Pan J
Clin Cancer Res; 2018 Aug; 24(15):3741-3754. PubMed ID: 29233905
[No Abstract] [Full Text] [Related]
3. Verification of EZH2 as a druggable target in metastatic uveal melanoma.
Jin B; Zhang P; Zou H; Ye H; Wang Y; Zhang J; Yang H; Pan J
Mol Cancer; 2020 Mar; 19(1):52. PubMed ID: 32127003
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional inhibition by CDK7/9 inhibitor SNS-032 suppresses tumor growth and metastasis in esophageal squamous cell carcinoma.
Zeng H; Yang H; Song Y; Fang D; Chen L; Zhao Z; Wang C; Xie S
Cell Death Dis; 2021 Nov; 12(11):1048. PubMed ID: 34741018
[TBL] [Abstract][Full Text] [Related]
5. Salinomycin effectively eliminates cancer stem-like cells and obviates hepatic metastasis in uveal melanoma.
Zhou J; Liu S; Wang Y; Dai W; Zou H; Wang S; Zhang J; Pan J
Mol Cancer; 2019 Nov; 18(1):159. PubMed ID: 31718679
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.
Wu Y; Chen C; Sun X; Shi X; Jin B; Ding K; Yeung SC; Pan J
Clin Cancer Res; 2012 Apr; 18(7):1966-78. PubMed ID: 22447844
[TBL] [Abstract][Full Text] [Related]
7. Activation of transmembrane receptor tyrosine kinase DDR1-STAT3 cascade by extracellular matrix remodeling promotes liver metastatic colonization in uveal melanoma.
Dai W; Liu S; Wang S; Zhao L; Yang X; Zhou J; Wang Y; Zhang J; Zhang P; Ding K; Li Y; Pan J
Signal Transduct Target Ther; 2021 May; 6(1):176. PubMed ID: 33976105
[TBL] [Abstract][Full Text] [Related]
8. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor.
Wang Y; Liu M; Jin Y; Jiang S; Pan J
Cancer Lett; 2017 Aug; 400():47-60. PubMed ID: 28455241
[TBL] [Abstract][Full Text] [Related]
10. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma
Zhou J; Jin B; Jin Y; Liu Y; Pan J
Theranostics; 2017; 7(6):1447-1462. PubMed ID: 28529629
[TBL] [Abstract][Full Text] [Related]
11. Elucidating the role of the FoxO3a transcription factor in the IGF-1-induced migration and invasion of uveal melanoma cancer cells.
Yan F; Liao R; Farhan M; Wang T; Chen J; Wang Z; Little PJ; Zheng W
Biomed Pharmacother; 2016 Dec; 84():1538-1550. PubMed ID: 27881235
[TBL] [Abstract][Full Text] [Related]
12. Arylsulfonamide 64B Inhibits Hypoxia/HIF-Induced Expression of c-Met and CXCR4 and Reduces Primary Tumor Growth and Metastasis of Uveal Melanoma.
Dong L; You S; Zhang Q; Osuka S; Devi NS; Kaluz S; Ferguson JH; Yang H; Chen G; Wang B; Grossniklaus HE; Van Meir EG
Clin Cancer Res; 2019 Apr; 25(7):2206-2218. PubMed ID: 30563937
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.
Calipel A; Landreville S; De La Fouchardière A; Mascarelli F; Rivoire M; Penel N; Mouriaux F
Clin Exp Metastasis; 2014 Jun; 31(5):553-64. PubMed ID: 24652072
[TBL] [Abstract][Full Text] [Related]
14. Kinome-wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics.
Bailey FP; Clarke K; Kalirai H; Kenyani J; Shahidipour H; Falciani F; Coulson JM; Sacco JJ; Coupland SE; Eyers PA
Pigment Cell Melanoma Res; 2018 Mar; 31(2):253-266. PubMed ID: 28972303
[TBL] [Abstract][Full Text] [Related]
15. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
Ambrosini G; Sawle AD; Musi E; Schwartz GK
Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
[TBL] [Abstract][Full Text] [Related]
16. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
Musi E; Ambrosini G; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
[TBL] [Abstract][Full Text] [Related]
17. Pristimerin effectively inhibits the malignant phenotypes of uveal melanoma cells by targeting NF‑κB pathway.
Zhang B; Zhang J; Pan J
Int J Oncol; 2017 Sep; 51(3):887-898. PubMed ID: 28766683
[TBL] [Abstract][Full Text] [Related]
18. Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression.
Gangemi R; Mirisola V; Barisione G; Fabbi M; Brizzolara A; Lanza F; Mosci C; Salvi S; Gualco M; Truini M; Angelini G; Boccardo S; Cilli M; Airoldi I; Queirolo P; Jager MJ; Daga A; Pfeffer U; Ferrini S
PLoS One; 2012; 7(1):e29989. PubMed ID: 22267972
[TBL] [Abstract][Full Text] [Related]
19. The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma.
Shu W; Zhu X; Wang K; Cherepanoff S; Conway RM; Madigan MC; Zhu H; Zhu L; Murray M; Zhou F
Cell Oncol (Dordr); 2022 Aug; 45(4):601-619. PubMed ID: 35781872
[TBL] [Abstract][Full Text] [Related]
20. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis.
Kageyama K; Ohara M; Saito K; Ozaki S; Terai M; Mastrangelo MJ; Fortina P; Aplin AE; Sato T
J Transl Med; 2017 Jun; 15(1):145. PubMed ID: 28645290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
